Patients with head and neck cancer: Are they frailer than patients with other solid malignancies?

Bras, Linda; Driessen, Daphne A J J; Vries, Julius de; Festen, Suzanne; Laan, Bernard F. A. M. van der; Leeuwen, Barbara L. van; Bock, Geertruida H. de; Halmos, György B.

doi:10.1111/ecc.13170

Cited by 43 publications

(41 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The diagnostic process in HNC is complex and time-consuming, often requiring biopsy under general anaesthesia and multiple imaging modalities for accurate staging. Moreover, HNC patients are a varied population with a high incidence of comorbidities and frailty [10]. An additional challenge in HNC patients is treatment planning: locally advanced disease requires multimodality therapy consisting of surgery and adjuvant (chemo)radiation or primary chemoradiation therapy.…”

Section: Introductionmentioning

confidence: 99%

Determinants of delay and association with outcome in head and neck cancer: A systematic review

Schoonbeek

Zwertbroek

Plaat

et al. 2021

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Introduction: Head and neck cancers (HNC) are relatively fast-growing tumours, and delay in treatment initiation is associated with tumour progression and adverse outcome. An overview of factors contributing to delay can provide critical insights on necessary adjustments to optimize care pathways. This systematic review aims to identify factors associated with delay and summarize the effect of delay on oncological outcome measures. Methods: A search strategy was conducted according to PRISMA guidelines to search electronic databases for studies assessing the carepathway interval (days between first visit in head and neck oncology center and treatment initiation) and/or time-to-treatment-initiation interval (days between histological diagnosis and treatment initiation) and 1) determinants of delay and/or 2) effect of delay on outcome within these timeframes. Due to heterogeneity between included studies, a meta-analysis was not possible. Results: Fifty-two studies were eligible for quantitative analysis. Non-Caucasian race, academic setting, Medicaid/no insurance and radiotherapy as primary treatment were associated with delay. Advanced tumour stage was related to increased time-to-treatment initiation in the four common sites combined (oral cavity, oropharynx, hypopharynx, larynx). Separate determinants for delay in different tumour locations were identified. In laryngeal, oral cavity cancer and the four common HNC sites combined, delay in start of treatment is associated with decreased overall survival, although no cut-off time point could be determined. Conclusion: Race, facility type, type of insurance and radiotherapy as primary treatment were associated with delay and subsequent inferior survival in the four common sites combined.

show abstract

Section: Introductionmentioning

confidence: 99%

Determinants of delay and association with outcome in head and neck cancer: A systematic review

Schoonbeek

Zwertbroek

Plaat

et al. 2021

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Patient-reported data, including data about quality of life, are collected for about 70–80% of patients depending on a tumor group. The examples of quality of life [12, 14] and imaging [15] data analysis could be found in previous studies.…”

Section: Resultsmentioning

confidence: 99%

The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient’s perspective

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundUnderstanding cancer heterogeneity, its temporal evolution over time, and the outcomes of guided treatment depend on accurate data collection in a context of routine clinical care. We have developed a hospital-based data-biobank for oncology, entitled OncoLifeS (Oncological Life Study: Living well as a cancer survivor), that links routine clinical data with preserved biological specimens and quality of life assessments. The aim of this study is to describe the organization and development of a data-biobank for cancer research.ResultsWe have enrolled 3704 patients aged ≥ 18 years diagnosed with cancer, of which 45 with hereditary breast-ovarian cancer (70% participation rate) as of October 24th, 2019. The average age is 63.6 ± 14.2 years and 1892 (51.1%) are female. The following data are collected: clinical and treatment details, comorbidities, lifestyle, radiological and pathological findings, and long-term outcomes. We also collect and store various biomaterials of patients as well as information from quality of life assessments.ConclusionEmbedding a data-biobank in clinical care can ensure the collection of high-quality data. Moreover, the inclusion of longitudinal quality of life data allows us to incorporate patients’ perspectives and inclusion of imaging data provides an opportunity for analyzing raw imaging data using artificial intelligence (AI) methods, thus adding new dimensions to the collected data.

show abstract

“…Surgery was performed between August 2010 and December 2016. Patients from the PICNIC cohort were earlier described [ 5 , 6 , 13 , 14 ], as well as the patients from the PICNIC-B-HAPPY cohort [ 15 , 16 ].…”

Section: Methodsmentioning

confidence: 99%

Preoperative Inflammatory Markers as a Predictor of Three-Year Overall Survival in Older Cancer Patients Undergoing Oncologic Surgery

Brattinga

Rutgers

Haan

et al. 2021

Cancers

View full text Add to dashboard Cite

Oncologic surgery results in substantially higher morbidity and mortality rates in older patients compared to younger patients, yet little is known about the relation between the preoperative inflammatory state and postoperative outcome in the specific group of older cancer patients. The aim of this study was to examine whether preoperative inflammatory markers could be a predictor of overall survival in older patients undergoing elective surgery for a solid malignant tumor. Patients 65 years and older undergoing surgery for a solid malignant tumor were included in a prospective cohort study. Inflammatory markers C-reactive protein (CRP), interleukin-1 beta (IL-1β), IL-6, IL10, IL-12 and tumor necrosis factor-alpha (TNF-α) were measured in plasma samples preoperatively. The main outcome was overall survival three years after surgery. Between 2010 and 2016, 328 patients with a median age of 71.5 years (range 65–89) were included. A significantly higher mortality rate three years after surgery, was found in patients with high preoperative plasma levels of CRP and IL-6 (p = 0.013 and p = 0.046, respectively). In multivariate analysis, corrected for variables such as age, disease stage, frailty, comorbidities, type of surgery and complications, a preoperative plasma level of CRP ≥ 10 mg/L was an independent prognostic factor for inferior overall survival three years after surgery (multivariate hazard ratio 1.50, 95% confidence interval 1.04–2.16, p = 0.031). Also, for the specific group of patients with colorectal cancer, a preoperative plasma level of CRP ≥ 10 mg/L was a prognostic factor for inferior survival three years after surgery (multivariate hazard ratio 2.40, 95% confidence interval 1.20–4.81, p = 0.014). Preoperative elevated plasma level of CRP is an independent unfavorable prognostic factor for overall survival three years after oncologic surgery. This gives more insight into the relationship between inflammation and survival in older cancer patients, and might contribute to risk stratification for poor outcome after surgery in older cancer patients.

show abstract

Patients with head and neck cancer: Are they frailer than patients with other solid malignancies?

Cited by 43 publications

References 47 publications

Determinants of delay and association with outcome in head and neck cancer: A systematic review

Determinants of delay and association with outcome in head and neck cancer: A systematic review

The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient’s perspective

Preoperative Inflammatory Markers as a Predictor of Three-Year Overall Survival in Older Cancer Patients Undergoing Oncologic Surgery

Contact Info

Product

Resources

About